

1 **Inhibition of itch by neurokinin 1 receptor (Tacr1) -expressing ON cells in the rostral**
2 **ventromedial medulla**

3 **Authors:** Taylor Follansbee^{1,2}, Dan Domocos³, Eileen Nguyen⁴, Amanda Nguyen¹, Aristeia
4 Bountouvas¹, Lauren Velasquez¹, Mirela Iodi Carstens¹, Keiko Takanami⁵, Sarah E. Ross⁴, E.
5 Carstens¹

6 ¹Department of Neurobiology, Physiology and Behavior, Univ. of California, Davis CA 95616,
7 USA

8 ²Department of Neuroscience, Johns Hopkins University, Baltimore MD 21205

9 ³Department of Anatomy, Animal Physiology and Biophysics, University of Bucharest,
10 Bucharest, Romania

11 ⁴Pittsburgh Center for Pain Research and Department of Neurobiology, University of Pittsburgh,
12 Pittsburgh, PA 15213, USA

13 ⁵Dept. of Environmental Life Science, National Nara Women University, Nara Japan

14

15

16 **Abstract**

17 The rostral ventromedial medulla (RVM) is important in descending modulation of spinal
18 nociceptive transmission, but it is unclear **if the RVM also modulates** spinal pruriceptive
19 transmission. RVM ON cells are activated by noxious algescic and pruritic stimuli and are
20 pronociceptive. Many RVM-spinal projection neurons express the neurokinin-1 receptor
21 (Tacr1), and ON-cells are excited by local administration of substance P (SP). We hypothesized
22 that Tacr1-expressing RVM ON cells exert an inhibitory effect on itch opposite to their
23 pronociceptive action. Intramedullary microinjection of SP significantly potentiated RVM ON
24 cells and reduced pruritogen-evoked scratching **while producing mild mechanical sensitization**.
25 Chemogenetic activation of RVM Tacr1-expressing RVM neurons also reduced acute
26 pruritogen-evoked scratching. Optotagging experiments confirmed RVM Tacr1-expressing
27 neurons to be ON cells. We conclude that Tacr1-expressing ON cells in RVM play a significant
28 role in the **modulation of** pruriceptive transmission.

29

30 **Introduction**

31 The transmission of somatosensory information in the spinal cord is under top-down modulation
32 and has been extensively studied in the context of pain signaling. Descending modulation of
33 pain is reflected by phenomena such as expectation (placebo and nocebo), diffuse noxious
34 inhibitory control (DNIC) and conditioned pain modulation (CPM) (Bartels et al., 2018; Chebbi et
35 al., 2014; Damien et al., 2018; Le Bars, 2002; Lockwood & Dickenson, 2020). Descending
36 modulation is also thought to underlie stress mediated changes in pain threshold, with acute
37 stress inhibiting and chronic stress facilitating nociceptive transmission (Butler & Finn, 2009;
38 Fields, 2000; Jennings et al., 2014; Wager & Atlas, 2015). Recent studies indicate that the
39 spinal transmission of pruriceptive information is also under descending modulatory influences,
40 **but** it is not known whether itch is modulated in the same way as pain (Agostinelli & Bassuk,
41 **2021; Gao et al., 2021; Gao et al., 2019; Koga et al., 2020; Liu et al., 2019; Samineni et al.,**
42 **2019; Wu et al., 2021).**

43 The rostral ventromedial medulla (RVM) contains neurons with descending projections to the
44 spinal cord which bidirectionally modulate spinal nociceptive transmission (Fields, 2000; Fields
45 & Basbaum, 1978; Fields & Heinricher, 1985; Heinricher et al., 2009; Millan, 2002; Ossipov et
46 al., 2014). RVM ON cells are excited and OFF cells are inhibited by noxious stimulation just
47 prior to a nocifensive withdrawal reflex, and respectively facilitate and inhibit spinal nociceptive
48 transmission (Fields, 2004; Fields et al., 1983). Increased ON cell and decreased OFF cell
49 firing are thought to contribute to the chronification of pain (Ossipov et al., 2014). **Neutral** cells
50 do not exhibit any significant response to noxious stimulation (Barbaro et al., 1986). **Many** RVM
51 neurons project to the spinal cord via the dorsolateral funiculus (DLF), terminating in layers I, II
52 and V, and are implicated in the analgesic effects of opioids. It is still unknown whether the
53 RVM ON and OFF cells are involved in the modulation of itch transmission.

54 A recent study reported that neurons in the periaqueductal gray (PAG) expressing Tac1, the
55 gene for substance P (SP), project to and make an excitatory glutamatergic connection with
56 neurons in the RVM (Gao et al., 2019). Activation of these PAG neurons promotes scratching. A
57 population of GABAergic neurons originating in the RVM synapse onto spinal neurons that
58 express the gastrin releasing peptide receptor (GRPR) (Liu et al., 2019), which are considered
59 to be essential for spinal pruriceptive transmission (Carstens et al., 2020). Activation of
60 GABAergic and inhibition of glutamatergic neurons in PAG reduced scratching behavior in both
61 acute and chronic itch conditions (Samineni et al., 2019). Furthermore, pruritogens were shown
62 to excite ON and inhibit OFF cells (Follansbee et al., 2018). Cervical cold block, which
63 diminishes activity in descending modulatory pathways, decreased pruritogen-evoked activity
64 and facilitated algogen-evoked activity of spinal cord neurons implying opposing effects of
65 descending modulatory pathways on nociceptive and pruriceptive transmission (Carstens et al.,
66 2018). The current evidence suggests that at least two classes of PAG neurons, via connections
67 to RVM cells, exert bimodal effects on the spinal pain and itch signaling pathways. Since
68 activation of PAG *tac1r* neurons facilitates itch this implies that activation of RVM Tacr1-
69 expressing neurons may likewise facilitate itch. However, RVM ON cells are known to facilitate
70 pain, and thus may have an opposing effect on itch transmission.

71 Here we investigated the role of Tacr1-expressing RVM neurons in itch modulation. In the
72 present study, we used pharmacological and opto/chemogenetic methods to selectively activate
73 RVM Tacr1-expressing cells, which we hypothesize represent a population of RVM ON cells,
74 and assessed the effects on pruritogen-evoked scratching, and thermal and mechanical
75 nociceptive behavior. When RVM Tacr1-expressing cells were activated we observed that itch
76 related behaviors were inhibited, while **producing mild mechanical sensitization**. We used
77 optotagging to characterize these RVM Tacr1-expressing neurons as RVM ON cells. These

78 results are the first to demonstrate an inhibitory effect of RVM ON cells on itch transmission,
 79 contrary to their known pronociceptive function.

80 Results

81 SP enhances RVM ON-cell responses to pinch

82 In rats, responses of RVM ON cells were potentiated by intramedullary microinjection of the
 83 Tacr1 agonist SP (Budai et al., 2007) and we wished to determine whether this is true in mouse.
 84 We identified RVM ON cells using *in vivo extracellular electrophysiological recordings*, with the
 85 criterion that noxious pinch elicited a > 30% increase in firing that preceded the onset of the
 86 hindpaw withdrawal. Using a microinjection cannula attached to a recording microelectrode (Fig.
 87 1A), SP or saline was microinjected while recording from an ON cell *in anesthetized mice*.




Figure 1: Effects of intramedullary microinjection of SP on RVM ON cells and itch and pain behavior. (A) SP or saline was microinjected while recording from single ON cells. (B) Peristimulus-time histogram of ON cell response to pinch before (left) and 5 min after local microinjection of SP (right). (C) **Normalized** firing rate of ON cells following local microinjection of saline (blue, n = 8) or SP (red, n = 8) at time indicated by arrow. ON cells showed a significant increase in evoked firing following SP injection compared with saline (*; p = 0.0133, 2-way ANOVA, **bolded lines: mean responses; error bars SEM**). Male mice were used in these experiments. (D) Lesion sites from the RVM ON cell recordings. Numbers to right indicate Bregma coordinates. (E) An implanted intramedullary microinjection cannula allowed assessment of itch and pain behavior after injection of SP into RVM. (F, G) Graphs plot the number of scratch bouts elicited by intradermal injection of histamine (F) or chloroquine (G) for each mouse (red dots and lines), and mean scratch bouts (**black line**; error bars: SEM), following intramedullary microinjection of saline or SP. Experiments with saline and SP microinjections were conducted at least 7 days apart. Microinjection of SP significantly attenuated histamine- and chloroquine-evoked scratching (F, G). (H) Mechanical withdrawal thresholds were reduced by intramedullary SP. (I) Thermal withdrawal latency was not significantly affected by intramedullary SP. *p < 0.05, **p < 0.01, ***p < 0.001. n = 5-7 males, 3 females/ group.

88 Microinjection of SP potentiated pinch-evoked responses (Fig. 1B). Following SP microinjection,
89 normalized responses of ON cells to repeated pinch stimuli were significantly increased (Fig.
90 1C). The enhancement of responses lasted > 1 hr. Histologically recovered recording sites
91 were located within the RVM and adjacent regions of the medullary reticular formation (Fig. 1D).
92 These results show that, similar to rats, RVM ON cells in the mouse are potentiated following
93 localized injection of SP.

94 Intramedullary SP inhibits scratching

95 Since RVM ON cells are potentiated following injection of SP, we next tested if intramedullary
96 microinjection of SP affected itch and pain related behaviors. Mice were implanted with an
97 intramedullary microinjection cannula dorsal to the RVM to allow microinjection of SP or vehicle
98 (Fig. 1E). The number of scratch bouts elicited by intradermal injection of histamine was
99 significantly lower following intramedullary microinjection of SP compared to saline vehicle (Fig.
100 1F). Scratching elicited by intradermal injection of chloroquine was also significantly reduced
101 following intramedullary injection of SP compared to saline (Fig. 1G).

102 There was a significant decrease in mechanical force to elicit a hindlimb withdrawal following
103 intramedullary SP compared to vehicle injection (Fig. 1H), indicating **mild mechanical**
104 **sensitization**. There was no significant effect of intramedullary SP injection on thermal hindpaw
105 withdrawal latency (Fig. 1I). **We observed that both male and female mice showed a reduced**
106 **hindlimb withdrawal, but that males had a significantly higher force for both saline and sp**
107 **injection when compared with females (Supplemental Fig. 6d). Thus, activation** of RVM Tacr1-
108 **expressing neurons**, through intramedullary injection of SP, resulted in facilitation of mechanical
109 nociceptive behavior and inhibition of pruritogen-evoked scratching behavior.

110 Targeted expression of DREADDs in RVM Tacr1 expressing neurons




Figure 2: In *Tacr1 cre^{+/+}* mice receiving AAV-DIO-hM3Dq-mCherry injections in the RVM, mCherry strongly colocalized with Tacr1 expression and clozapine strongly increased Tacr1 cellular activity. (A-C): images of RVM cells expressing mCherry (A), anti-Tacr1 antibody (B), and double-labeled cells (C). (D): 84% of cells exhibited co-localization of Tacr1 and mCherry. (E-G): images of RVM neurons expressing mCherry (E), c-fos (F) and double-labeled cells (G) after clozapine administration in mice that had received AAV-DIO-hM3Dq-mCherry injections in RVM. (H): In DREADDs mice, injection of clozapine significantly increased the number of c-fos+ neurons when compared with saline injection. (I-K): images of RVM neurons expressing mCherry (I), c-fos (J) and double-labeled cells (K) after clozapine administration in mice that had received AAV-DIO-mCherry injections in RVM. (L): Following administration of clozapine, the number for c-fos+ neurons was significantly greater when compared to vector controls. N = 3-10/group, *p < 0.05, unpaired students t test.

111 We next wanted to determine whether activation of RVM Tacr1 expressing neurons, would
 112 modulate itch related behaviors. To selectively target Tacr1-expressing neurons in the RVM we
 113 employed a chemogenetic approach. AAV-DIO-hM3dqmCherry was injected into the RVM of
 114 Tacr1 cre mice, resulting in selective expression of hM3Dq in Tacr1-expressing neurons (84%
 115 expression of DREADDs in Tacr1 positive cells, Fig. 2A-C).

116 To activate the DREADDs (hM3Dq), clozapine was injected at a dose 0.01 mg/kg (Gomez et
 117 al., 2017). This dose of clozapine was sufficient to produce increased activity of DREADDs-

118 expressing neurons measured by c-fos expression. When we tested DREADDs mice there was
119 a significant increase in the number of c-fos positive cells following ip administration of
120 clozapine (62.22% +/- 11.61%) when compared with ip saline (15.66% +/- 1.678%) (Fig. 2h). In
121 addition, we tested if clozapine elicited a greater increase in c-fos expression in DREADDs
122 compared to control vector (mCherry) mice. Indeed, following clozapine administration, the
123 number of c-fos positive mCherry-expressing cells was significantly higher in DREADDs
124 (hM3Dq-mCherry) mice (68.98% +/- 11.83%) compared with neurons from control vector
125 (mCherry) mice (36.02% +/- 5.96%; Fig. 3 I-L, $p = 0.0158$). These results show that injection of
126 clozapine activates hM3Dq, which is expressed by RVM Tacr1 neurons.

127 Activation of RVM Tacr1 expressing neurons inhibits acute itch

128 To test the functional role of the RVM Tacr1-expressing population of neurons in itch
129 modulation, we used DREADDs (hM3dq) to activate these neurons during pruritogen-evoked
130 scratching behaviors. Activation of DREADD-expressing RVM neurons in Tacr1 cre mice using
131 clozapine significantly attenuated pruritogen-evoked scratching behavior. After clozapine
132 administration (0.01 mg/kg, ip) there was a significant reduction in scratch bouts elicited by
133 intradermal histamine as compared to systemic administration of saline vehicle (Fig. 3C). There
134 was a significantly stronger inhibition of histamine-evoked scratching behavior in male
135 compared to female mice (Supplemental Fig. 6e). Similarly, there was a significant reduction in
136 chloroquine-evoked scratching (Fig. 4D). In contrast, clozapine administration had no significant
137 effect on the withdrawal threshold to mechanical von Frey stimuli (Fig. 4E) or withdrawal latency
138 to thermal stimulation (Fig. 3F). Administration of clozapine in control vector (Tacr1-mCherry)
139 mice had no significant effect on scratching behavior elicited by intradermal injection of
140 histamine (Fig. 3C) or chloroquine (Fig. 3D). Likewise, clozapine administration had no
141 significant effect on mechanical (Fig. 3E) or thermal hindpaw withdrawals in vector controls (Fig.
142 3F). Finally, neither a low (0.01 mg/kg) nor a higher dose (0.1 mg/kg) of clozapine had any




Figure 3: Chemogenetic activation of RVM Tac1 expressing neurons inhibits itch related behavior. (A) AAV5-DIO-hM3Dq-mCherry or AAV5-DIO-mCherry was injected into the RVM of Tac1 cre mice. (B) Expression of hM3Dq-mCherry was limited to the RVM. Gt: gigantocellularis; RMg: raphe magnus; RPa: raphe pallidus. (C) Administration of clozapine caused a significant reduction in histamine-evoked scratching (7 males, 7 females) in hM3Dq expressing mice, but not in control vector mice (6 males, 3 females). (D) Administration of clozapine caused a significant reduction in chloroquine-evoked scratching in hM3Dq mice (7 males, 8 females) but not in control vector mice (6 males, 4 females). (E) Clozapine administration did not significantly change mechanical withdrawal thresholds in hM3Dq (7 males, 8 females) or control vector mice (6 males, 4 females). (F) Clozapine administration did not significantly change thermal withdrawal thresholds in hM3Dq (7 males, 8 females) or control vector mice (6 males, 4 females). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, Two-way ANOVA with Sidaks multiple comparison test.

143 significant effect on histamine- or chloroquine-evoked scratching behavior or on mechanically-
 144 or thermally-evoked paw withdrawals in wildtype mice (Supplemental Fig. 2).

145 Our results were independently confirmed using a separate line of tac1Rcre-ER mice (Huang et
 146 al. 2016), that received intra-RVM microinjection of the excitatory DREADD AAV2-DIO-hM3dq-
 147 mCherry. Chemogenetic activation using CNO significantly reduced chloroquine evoked
 148 scratch bouts (Supplemental Fig. 1A) and spontaneous scratching behavior (Supplemental
 149 1B), and also significantly reduced the von Frey mechanical withdrawal threshold (Supplemental

150 Fig. 1C) with no effect on thermal withdrawal latency (Supplemental Fig. 1D). CNO had no
151 effect in the control vector mice. Independent experiments in two lines of Tacr1 cre mice
152 support the conclusion that activation of RVM Tacr1 expressing neurons inhibits pruritogen
153 evoked scratching behavior.

154 RVM Tacr1 expressing neurons inhibit chronic itch

155 Since activation of RVM Tacr1-expressing neurons inhibited acute pruritogen-evoked scratching
156 behavior, we next wanted to determine whether chronic itch related behaviors would be
157 affected. We used the imiquimod model of psoriasisiform dermatitis in Tacr1 cre mice receiving
158 intra-RVM injection of hM3Dq or control vector. Mice were treated daily with topical application
159 of 5% imiquimod cream for 5 days. This resulted in a significant increase in spontaneous
160 scratching on treatment day 3 (Fig. 4A, dark blue) and significantly increased alloknesis scores
161 on treatment days 1, 3 and 5 (Fig. 4D, dark blue). Application of vehicle (Vanicream) had no
162 effect on spontaneous scratching or alloknesis (Follansbee et al., 2019). Following
163 administration of clozapine on day 5, there was a significant reduction in the number of
164 spontaneous scratch bouts (Fig. 4A, light blue). Fig. 4B shows that scratch bouts in individual
165 animals were significantly reduced after the administration of clozapine. Clozapine
166 administered on days 3 and 5 also significantly reduced alloknesis scores (Fig. 4D, light blue).
167 Fig. 5E shows significant reductions in alloknesis scores of individual animals after as compared
168 to before clozapine. Mice that received intra-RVM microinjection of control vector also showed
169 significant increases in spontaneous scratching (Fig. 4A, dark green) and alloknesis scores (Fig.
170 4D, dark green) following imiquimod treatment. Administration of clozapine did not significantly




Figure 4: Chemogenetic activation of RVM Tacr1 neurons reduces spontaneous scratching and alloknesis in the imiquimod model of chronic psoriasisiform itch. (A) Application of imiquimod (1%, 0.05 g, Taro) once per day produced a significant increase in spontaneous scratching at day 3 for both DREADDs (dark blue) and control vector (dark green) mice (n = 4 males, 4 females/group). Following clozapine, there was a significant reduction in spontaneous scratching on day 5 for the DREADDs mice (dashed light blue) but no significant change in control vector mice (dashed light green). (B) Graph shows individual DREADDs animals' spontaneous scratch bouts pre- and post-clozapine. Following clozapine there was a significant reduction in scratching. Blue: individual counts; red: mean +/- SEM. (C) Graph as in B for mice in vector control group, in which clozapine had no significant effect. Green: individual counts; red: mean +/- SEM. (D) Imiquimod induced significant increases in alloknesis scores on day 1, 3 and 5 of treatment in DREADDs (dark blue) and vector control (dark green) mice. Following clozapine administration on days 3 and 5 there were significant reductions in alloknesis scores for the DREADDs mice (dashed light blue) but not control vector groups (dashed light green). (E) Clozapine resulted in a significant reduction in alloknesis scores (format as in B). (F) Clozapine had no effect on alloknesis scores in vector controls (format as in C). *p < 0.05, **p < 0.01, ***p < 0.001.

171 affect spontaneous scratching (Fig. 5C) or alloknesis scores (Fig. 5F) in these mice. These
 172 results show that activation of RVM Tacr1-expressing neurons reduces itch related behaviors in

173 a model of chronic itch in addition to acute pruritogen-evoked scratch bouts.

174 RVM ON cells express Tacr1

175 Previous reports had shown, in rats, that RVM ON cells were facilitated by local microinjection
176 of SP (Budai et al., 2007; Zhang & Hammond, 2009) and ablation of RVM neurons which
177 express Tacr1, was antihyperalgesic (Khasabov et al., 2017), consistent with a pronociceptive
178 role for RVM ON cells.

179 We used Tacr1 cre mice which were injected with an AAV encoding channelrhodopsin
180 (AAV5:DIO-ChR2-eYFP). Four weeks later, the mice were anesthetized with sodium
181 pentobarbital for single-unit recording with a microelectrode whose tip extended **a few hundred**
182 **micrometers** beyond the tip of an optic fiber it was affixed to (Fig. 5A). Injected mice exhibited
183 robust expression of eYFP in the RVM (Fig. 5B). ON and OFF cells were identified based on
184 their response to a pinch stimulus. Once identified, blue light (473 nm, **0.25-5 mW**) was applied
185 and the cell was tested for entrainment to the light **stimulus**. Fig. 5C shows an example of an
186 ON cell in RVM that responded to pinch prior to the onset of EMG activity and was faithfully
187 entrained to 10 hz light stimulation (Fig. 5D). This neuron received a total of 37 light pulses at 2
188 hz and fired 32 action potentials within 20 ms of the light onset (Fig. 5E) with a calculated
189 efficiency index of 0.86 (see below), and an average latency of 8.14 ms. The latencies
190 measured presently compare favorably with those reported previously for hippocampal neurons
191 (Zhang et al., 2013). The latency, or on rate, of neuronal activation differs by cell type (Herman
192 et al., 2014) and increases with diminishing light density (Lin et al., 2009). Out of 22 identified
193 ON cells, 17 were entrained to the light stimulus, 1 was inhibited and 4 were not affected (Fig.
194 **6F**). It is possible that our estimate is an under representation since viral transduction was not
195 completely efficacious. Since the majority of RVM ON cells were entrained to light stimulation,
196 we conclude that the majority of ON cells likewise express Tacr1.

197 While our primary interest was RVM ON cells, we wanted to determine whether Tacr1 is also
198 expressed in other cell types, such as RVM OFF cells. During our recordings we often found
199 RVM OFF cells. Out of 14 identified OFF cells, **none were directly activated by the light**
200 **stimulus, with 7 showing** a clear inhibitory response to the light stimulation **while the other 7**
201 **were unaffected** (Fig. 5F). Often the **degree of** inhibition of the OFF cell increased
202 proportionately to the stimulation frequency (Fig. 5G-I). These results support the hypothesis
203 that RVM ON cells provide an inhibitory input onto RVM OFF cells (Fields & Heinricher, 1989)
204 and may underlie the RVM OFF cell mediated pause during noxious stimulation.

205 Occasionally **Neutral** cells were identified by their response to optic stimulation ($n = 3$), and
206 each was strongly entrained (Fig. 5F). **Since Neutral cells are numerous, not affected by**
207 **noxious stimulation and their contribution, if any, to descending modulation is unknown, they**
208 **were not investigated further.** We thus conclude that while most presently-recorded light-
209 sensitive cells were ON cells, other cell types including **Neutral** cells also expresses Tacr1.

210 To validate our results from optotagging, we used several metrics to determine whether a light-
211 sensitive neuron was truly entrained to the optic stimulus. We assumed that each optic stimulus
212 was likely to directly excite a neuron expressing ChR2 and tested this in different ways. An
213 efficiency index was calculated to determine whether a neuron was entrained to the optic
214 stimulus, by counting the number of evoked action potentials divided by the number of optic
215 stimuli (Supplemental Fig. 3). The 3 **Neutral** cells had the highest efficiency index (>1), which
216 was due to occasional firing of “doublet” action potentials in response to the optic stimulus
217 (Supplemental Fig. 3C,D). ON cells classified as light sensitive also had a high efficiency index,
218 which decreased with increasing optic stimulation frequency most likely due to desensitization of
219 ChR2. We additionally assumed that the neuronal firing rate would reflect the number of optic
220 stimuli. Indeed, the neuronal firing rate in light sensitive neurons increased with the stimulation
221 frequency, while non-light sensitive neurons showed no change (Supplemental Fig. 4). In

222 neurons which were inhibited by optic stimulation, there was a decrease in firing rate following
223 light stimulation (Supplemental Fig. 4, OFF cells). Finally, we assumed that the light-evoked




Figure 5: Optotagging of RVM Tacr1 neurons. (A) RVM cells were recorded with a microelectrode coupled to an optic fiber. (B) Injection of AAV-ChR2-eYFP in the RVM of Tacr1 cre^{+/+} mice caused strong expression of eYFP. (C) ON cells were identified based on their pinch-evoked response that preceded the hindlimb withdrawal as monitored by EMG in biceps femoris. (D) Cells identified as RVM ON cells were optically stimulated (5 mW, 472nm). This neuron faithfully responded to each pulse in a 5 Hz train. (E) Light entrainment was analyzed by creating peristimulus-time histograms of action potentials that occurred within a 20 msec window following the onset of each light pulse. This neuron responded consistently at a latency of approximately 8.14 msec with a calculated efficiency index of 0.86. (F) Distribution of RVM ON, OFF and Neutral cells which were excited (red), inhibited (blue), or not affected (yellow) by optic stimulation. (G) Application of a pinch stimulus elicited a hindlimb withdrawal (dotted line) and a pause in firing that is typical of OFF cells. (H) There was an intermittent decrease in OFF cell firing during 5 Hz optic stimulation and a (I) total cessation of firing during 20 Hz optic stimulation. (J) Lesion sites from the optotagging recordings of RVM ON (red circles), OFF (blue triangles) and NEUTRAL cells (green squares). Numbers to right indicate Bregma coordinates.

224 latency of neuronal action potentials would be consistent. For the population of light-sensitive
225 ON cells, the average latency of responses to the optic stimuli delivered at 2 Hz was 7.6 (+/-
226 1.12) ms (Supplemental Fig. 5). Thus, these experiments strongly support the hypothesis that
227 the majority of RVM ON cells express Tacr1.

228 Discussion

229 Previous studies indicate a pronociceptive role for SP acting at Tacr1 expressing neurons in
230 RVM (Budai et al., 2007), many of which have descending spinal projections (Pinto et al., 2008).
231 A novel finding of the present study is that pharmacological and chemogenetic activation of
232 Tacr1-expressing RVM neurons inhibited itch-related scratching behavior, **with mild mechanical**
233 **sensitization** and no effect on thermal nociception. Our optotagging experiments provide
234 evidence that **the majority of ON cells express Tacr1**. These results argue for a causal role of a
235 subpopulation of Tacr1-expressing ON cells in the inhibition of **itch-related scratching behavior**,
236 in contrast to their pronociceptive role.

237 Role of SP in RVM in descending modulation of pain and itch

238 SP (Ljungdahl et al., 1978) and Tacr1 (Saffroy et al., 2003) are present within the RVM. SP
239 acting in the RVM potentiated ON cells, induced pronociceptive behavioral effects and
240 sensitized spinal wide dynamic range dorsal horn neurons (Budai et al., 2007; Khasabov et al.,

241 2017). SP appears not to be released in the RVM in the absence of injury, but is released
242 under inflammatory conditions elicited by CFA or capsaicin to induce Tacr1-dependent
243 hyperalgesia (Brink et al., 2012; Hamity et al., 2010; Khasabov et al., 2017). The present study
244 expands on this work in important ways. Firstly, we confirm that SP potentiates noxious pinch-
245 evoked responses of mouse RVM ON cells. Secondly, our optotagging data provide evidence
246 that the Tacr1-expressing neurons are ON cells. Importantly, our results support a role for
247 these neurons in descending inhibition of acute and chronic itch. Intra-RVM microinjection of
248 SP or chemogenetic activation of Tacr1-expressing neurons in two different Tacr1 cre lines
249 significantly decreased pruritogen-evoked as well as chronic itch related scratching behavior,
250 while facilitating mechanical nociception in most experiments with no effect on thermal
251 nociception. This latter observation contrasts with a previous report that intra-RVM
252 microinjection of a SP agonist enhanced thermal nociceptive behavior in rats(Khasabov et al.,
253 2017) a discrepancy that might be attributed to a species difference.

254 **Descending Modulation of Itch**

255 Optogenetic activation of GABAergic neurons in RVM facilitated mechanical, but not thermal
256 nociception in mice (François et al., 2017), consistent with our data. The latter authors
257 suggested that the GABAergic RVM neurons might represent ON cells, which descend to
258 presynaptically inhibit mechanonociceptor input onto spinal inhibitory enkephalinergic
259 interneurons that in turn contact the spinal mechanonociceptive pathway. Thus, activation of the
260 descending GABAergic neurons would facilitate mechanical nociception via disinhibition.

261 **Our study shows that RVM Tacr1 neurons represent a population of RVM ON cells, which when**
262 **activated, reduce pruritogen-evoked scratching. A limitation of this study is that we were not**
263 **able to directly demonstrate that inhibition of spinal pruriceptive transmission caused the**
264 **reduction in scratching behavior. Previous studies have shown that 31% of functionally identified**
265 **RVM ON cells (Vanegas et al., 1984), and 42.5% of Tacr1-expressing RVM neurons (Pinto et**

266 al., 2008), project to the spinal cord, supporting the descending modulation of spinal itch
267 processing. Moreover, recent studies report that activation of spinal projection neurons
268 originating in the locus coeruleus (Koga et al., 2020) or somatosensory cortex (Wu et al., 2021)
269 suppress itch-related scratching behavior. Given this and the historical evidence of the spinal
270 action of RVM ON cells, the most parsimonious explanation is that RVM Tacr1-expressing
271 neurons with descending axons exert an inhibitory effect on spinal pruriceptive transmission to
272 reduce scratching behavior. However, we cannot exclude the possibility that Tacr1-expressing
273 RVM neurons lacking spinal projections exert an antipruritic effect via an unknown supraspinal
274 action.

275 It was recently reported that activation of neurons in RVM that express the G-protein-coupled
276 estrogen receptor (GPER) suppresses signs of acute and chronic itch (Gao et al., 2021). It is
277 currently not known if GPER-expressing neurons co-express Tacr1.

278 Electrical stimulation of the PAG inhibited nocifensive behavior in rats (Mayer et al., 1971;
279 Reynolds, 1969), and the PAG projects directly to the RVM (Behbehani & Fields, 1979).
280 Activation of PAG GABAergic neurons, and inhibition of glutamatergic neurons, reduced
281 scratching behavior under both acute and chronic itch conditions (Samineni et al., 2019) but
282 facilitated nocifensive behaviors (Samineni et al., 2017). Activation of Tac1 (SP-expressing)
283 neurons in the PAG was shown to facilitate pruritogen-evoked scratching via release of
284 glutamate onto neurons in the RVM (Gao et al., 2019). In contrast, our results indicate that
285 activation of RVM Tacr1 neurons inhibited pruritogen-evoked scratching behavior. This
286 potentially represents a difference in the synaptic connections of PAG Tac1-expressing neurons
287 with glutamate- and/or Tacr1-expressing RVM neurons. Previous studies have reported
288 projections to RVM from SP-expressing neurons located in dorsolateral PAG, dorsal raphe
289 nucleus, cuneiform nucleus, and lateral hypothalamus (Chen et al., 2013; Holden & Pizzi, 2008;
290 Yin et al., 2014). It is thus possible that Tacr1-expressing RVM neurons that inhibit scratching

291 are activated by different SP inputs than the RVM neurons activated by PAG TAc1-expressing
292 neurons that facilitate scratching.

293 **Modality specific role of RVM ON cells**

294 For decades, the role of RVM ON cells has been considered facilitatory for spinal nociceptive
295 transmission. Our results suggest that the role of RVM ON cells is modality specific, with RVM
296 ON cells facilitating spinal nociceptive while inhibiting pruriceptive transmission. Pruritogens
297 and algogens similarly excited RVM ON and inhibited OFF cells, implying that the opposing
298 modulatory effects of ON cells on spinal nociceptive vs. pruriceptive transmission likely occurs
299 via separate spinal circuits. RVM ON cells have a GABA-mediated inhibitory connection to
300 spinal enkephalinergic neurons (François et al., 2017), raising the possibility that spinal
301 enkephalinergic tone accounts for the opposing effects on spinal nociceptive and pruriceptive
302 transmission. **Since pain suppresses itch, we cannot exclude the possibility that activation of**
303 **spinal pronociceptive circuitry inhibits itch transmission.**

304 **Treatment of chronic itch with Tacr1 antagonists**

305 The Tacr1 antagonists aprepitant and serlopitant were recently shown to be partially effective in
306 reducing chronic itch of various etiologies. Tacr1 antagonists might act at Tacr1 that is
307 expressed by spinothalamic and spinoparabrachial neurons (Todd, 2010) to reduce pruriceptive
308 transmission. Indeed, ablation of Tacr1-expressing spinal and medullary neurons reduces
309 pruritogen-evoked scratching behavior (Carstens et al., 2010). The present results suggest that
310 Tacr1 antagonists also have an opposite effect to block Tacr1-mediated descending inhibition of
311 itch. Systemic administration of Tacr1 antagonists thus appear to have offsetting supraspinal
312 and spinal effects, **potentially** explaining the limited efficacy of Tacr1 antagonists for chronic itch.

313 **Methods**

314 [Key Resource Table](#)

Reagent type (species) or resource	Designation	Source or reference	Identifiers
Tacr1 cre Mice/ c57 Background	Tacr1 cre	Dong Lab	
AAV hM3Dq	aav-hSyn-DIO-hM3Dq-mCherry	Addgene	44361-AAV5
AAV mCherry	aav-hSyn-DIO-mCherry	Addgene	50459-AAV5
AAV ChR2	aav-Ef1a-hChR2-mCherry	Addgene	20297-AAV5
Alexa 488 Secondary	Alexa Flour 488	Addgene	ab150077
anti Tacr1	Tacr1 antibody	SCBT	sc-365091 AF488
anti cfos	cfos antibody	Abcam	ab190289
DAPI	DAPI probe	ACD	320858
Substance P	Substance P (SP)	Tocris	1156/5
Histamine Dihydrochloride	Histamine (HA)	Sigma-Aldrich	H7250
Chloroquine Diphosphate	Chloroquine (CLQ)	Sigma-Aldrich	C6628
Pentobarbital Sodium	Pentobarbital	Sigma-Aldrich	P3761
Buprenorphine Hydrochloride	Bup	Amerisoucebergen	NDC42023-179-05
Prism 5	5 Prism	Graphpad	

315

316 Animals

317 Experiments were performed used wild type mice (c57BL/6j, Jackson Labs, Bar Harbor ME),
318 Tacr1 cre^{+/-} (courtesy of Dr. X. Dong, Johns Hopkins University), and Tacr1 cre^{+/-} mice (Huang
319 et al., 2016) of both sexes, 8-10 weeks of age, all on a C57Bl6 background. Mice were given
320 free access to food and water and housed under standard laboratory conditions. Mice were
321 housed in-lab and at the animal housing facility, with a natural light cycle and 12-hour light dark
322 cycle respectively. Mice were allowed to habituate for at least 3 days following transfer from the
323 animal facility to lab housing before use in behavioral experiments. Mice were cohoused with
324 between 1-4 mice/cage. All procedures were approved by the University of California, Davis and
325 University of Pittsburgh Animal Care and Use Committees and followed the ARRIVE guidelines
326 to the extent possible.

327 Pharmacologic agents

328 Clozapine was dissolved in saline and administered intraperitoneally (ip) at concentrations of
329 0.01 and 0.1 mg/kg. Clozapine-N-oxide (CNO; Tocris, Bristol UK) was dissolved in phosphate-
330 buffered saline and administered ip (5 mg/kg). In clozapine and CNO treated mice, experiments
331 were conducted 30 minutes following their administration. Histamine HCl (Sigma, St. Louis MO;
332 0.5% in 10 μ l) or chloroquine diphosphate salt (Sigma; 1% in 10 μ l) were dissolved in
333 physiological saline and administered intradermally via a 30 g needle in the nape of the neck.
334 Imiquimod cream (5%; Aldara, 50 mg; 3 M Health Care Limited, UK) was administered topically
335 once per day to shaved skin on the rostral back for 5 days.

336 Stereotaxic injections and cannula implantation

337 Animals were anesthetized with 2% isoflurane and placed in a stereotaxic head frame. A burr
338 hole was made in the calvarium and a Hamilton microsyringe loaded with virus was
339 stereotaxically placed such that the tip was at the injection site in RVM (RC: -5.5 to -5.8 mm,
340 ML: 0.0, DV: -4.2 to -6 mm). Virus (0.25-1 μ l) containing either AAV5: hSyn-DIO-hM3Dq-
341 mCherry (excitatory DREADD; Addgene, Watertown MA), AAV5: hSyn-DIO-mCherry (control
342 vector, Addgene), or AAV5: hSyn-DIO-ChR2-eYFP (Addgene) was injected into the RVM. Virus
343 was infused at an approximate rate of 100 nL/min. The injection needle was left in place for an
344 additional 15 min post-injection and then slowly withdrawn. The incision was closed using
345 Vetbond and animals were given ketofen (10 mg/kg ip) or buprenorphine (0.05 mg/kg ip) and
346 allowed to recover on a heating pad. A 4 week recovery period ensued prior to
347 experimentation.

348 For intracranial drug injections, an injection cannula (Plastics One, Roanoke VA) was implanted
349 stereotaxically with the tip targeted 1-2 mm above the RVM. For optogenetic stimulation,
350 following microinjection of AAV5: hSyn-DIO-ChR2-eYFP into RVM, an optic fiber (Doric Lenses,

351 Quebec Canada) was stereotaxically implanted at the target site. Dental cement was used to
352 affix the injection cannula or optic fiber to the skull. Post-implantation mice received
353 buprenorphine (0.05 mg/kg ip). Mice recovered for at least 4 weeks prior to experimentation.

354 Intracranial Drug Microinjection

355 Mice were habituated for 15 minutes prior to intracranial drug injection in clear cylindrical glass
356 enclosures and videotaped from above. Saline (0.5 μ l) or Substance P (SP, 0.5 μ l, 10 nmol,
357 Tocris, Minneapolis MN) was microinjected. Fifteen minutes post-injection mice were tested for
358 itch or pain behaviors as described below. Both male and female mice were used.

359 Chemogenetics

360 Thirty minutes after ip administration of saline, clozapine or CNO, behavioral testing
361 commenced.

362 Behavior

363 Scratching behavior: Scratch bouts were defined as back-and-forth hindpaw movements
364 directed to the rostral back, followed by biting the toes and/or placement of the hindpaw on the
365 floor. Scratch bouts elicited by histamine, chloroquine or saline vehicle were videotaped and
366 counts made by at least two blinded observers. Nociceptive behavioral assays (von Frey;
367 Hargreaves) were conducted by investigators blinded as to treatment. Successive behavioral
368 tests were conducted in pseudorandom order and spaced 1 week apart.

369 Von Frey: Mechanical sensitivity was measured in two ways. Mice stood on a mesh floor
370 allowing access to the plantar surface from below. Using the Chaplan up-down method
371 (Chaplan et al., 1994). calibrated von Frey filaments (North Coast Medical Inc.) were applied to
372 the plantar surface. Paw lifting, shaking, and licking were scored as positive responses.
373 Averaged responses were obtained from each hindpaw, with 3 min between trials on opposite

374 paws, and 5 min between trials on the same paw. Alternatively, the force at the moment of
375 hindpaw withdrawal was measured using an electronic von Frey device (2390; IITC, Woodland
376 Hills CA). Measurements were again taken from each hindpaw with 3 and 5 min between trials
377 on the same or opposite paw.

378 Hargreaves: Animals were acclimated on a glass plate held at 30°C (Model 390 Series 8, IITC
379 Life Science Inc.). A radiant heat source was applied to the hindpaw and latency to paw
380 withdrawal was recorded (Hargreaves et al., 1988). Two trials were conducted on each paw,
381 with at least 5 min between tests of opposite paws and at least 10 min between tests of the
382 same paw. To avoid tissue damage, a cut off latency of 20 sec was set. Values from both paws
383 were averaged.

384 In vivo single-unit recording

385 Adult mice (6 wk) mice were anesthetized with pentobarbital sodium (60 mg/kg, ip). The head
386 was secured in a stereotaxic frame and an opening was made in the occipital bone. The
387 animal's body temperature was maintained with a heating pad and external heating source.
388 Teflon coated silver wires were inserted into the biceps femoris to record electromyographic
389 (EMG) activity. A single-unit recording microelectrode (10 MOhm, Frederick Haer Inc., Bowdoin
390 ME) was coupled to a 33-gauge injection cannula such that the tip of the recording
391 microelectrode extended several μm beyond the tip of the injection cannula and was inserted
392 into the RVM. ON cells were identified by a hindpaw pinch-evoked increase in firing that
393 preceded the hindlimb withdraw reflex measured as EMG activity from fine wires inserted in the
394 biceps femoris. Once an ON cell was identified, either saline or SP (0.5 μl , 10 nmol) was
395 microinjected and changes in firing rate to repeated consistent pinch stimuli were recorded.
396 Responses to pinch stimuli were normalized to the initial response for each unit. Electrode
397 voltages were amplified and digitized (CED 1401, CED, Cambridge UK) and analyzed with
398 Spike2 (CED). At the end of the recording, a lesion was produced at the last recording site by

399 passing direct current through the microelectrode, the brain was harvested postmortem and
400 postfixed in 10% formalin.

401 Optotagging

402 At least 4 weeks following injection of AAV5: hSyn-DIO-ChR2-eYFP into RVM, single-unit
403 recordings were made from RVM as described above using a Tungsten microelectrode attached
404 to an optic fiber **such that the microelectrode tip extended a few hundred microns beyond the**
405 **optic fiber**. In most experiments ON cells were functionally characterized as described above,
406 and OFF cells were characterized by a pinch-evoked pause in ongoing activity that preceded
407 the withdrawal reflex. ON and OFF cells were then tested for entrainment to optic stimulation at
408 473 nm wavelength and **0.25 mW - 5 mW light output (5-20 Hz, 10ms pulse duration) from a**
409 **laser (Laserglow R471003GX)**. In some experiments, optic stimulation was used as to isolate
410 light-sensitive neurons, which were then identified as ON, OFF or **Neutral** based on their
411 response to pinch. Efficiency indices were calculated as the number of action potentials firing
412 within a 20 ms window following the onset of the optic stimulus divided by the total number of
413 optic stimulus pulses, and were used to determine whether a neuron was entrained to the optic
414 stimulus. Both male and female mice were used for all electrophysiological experiments.

415 Imiquimod Treatment

416 Imiquimod cream was applied topically to the shaved area on the rostral back once per day for 5
417 consecutive days. Treatment groups consisted of age-matched male and female NK-1-cre mice
418 that had received intra-RVM injection of AAV5: DIO-hM3Dq-mCherry or the control vector
419 AAV5: hSyn-DIO-mCherry. Imiquimod treatment induced signs of skin pathology including skin
420 scaling and erythema. As measures of chronic itch, we assessed spontaneous scratching, and
421 allodynia, 23 hours following imiquimod treatment. Mice were videotaped and tested between
422 10 AM and 5 PM, with each individual mouse tested at the same time each day. The mice were

423 habituated to glass cylinders for 3 successive days prior to recording. Animals were videotaped
424 from above for 30 min. Behavioral videos were analyzed by two blinded observers. Only
425 discrete bouts of spontaneous hindlimb scratches directed towards the application site were
426 counted, as described previously (Akiyama et al., 2016) and summed over the 30 min period.
427 Alloknesis was assessed as previously described (Akiyama et al., 2012). The mouse was
428 placed in an enclosed area and a 0.07g von Frey monofilament was applied to the perimeter of
429 the imiquimod application area 5 consecutive times. The alloknesis score consisted of the
430 number of immediately-occurring hindlimb scratch bouts directed to the stimulus site.

431 Immunofluorescence

432 Four weeks after intra-RVM injection of AAV5:hSyn-DIO-hM3Dq-mCherry or the control vector
433 (AAV5:hSyn-DIO-mCherry) in Tacr1 cre mice, clozapine (0.01 mg/kg, i.p.) was injected,
434 followed 1 hr later by perfusion (4% paraformaldehyde), harvesting of brains and post-fixation
435 overnight in 4% paraformaldehyde. Brains were sectioned (20 μ m) on a freezing microtome and
436 stained as free floating sections. DREADDs-expressing neurons were counterstained for Tacr1
437 expression with a conjugated Tacr1 antibody (D-11, sc-365091, Santa Cruz Biotechnology,
438 Dallas TX) at 1:50 overnight at 4°C. c-fos was stained with a primary c-fos antibody (ab190289,
439 Abcam, Cambridge UK) at 1:10,000 overnight at room temperature. Alexa Fluor 488 (ab15077,
440 Abcam) was applied at 1:2000 for 2 hours at room temperature. All slides were mounted with
441 vectashield and imaged with confocal microscopy. Staining intensity was measured relative to
442 the red fluorescence (from DREADDs) and was quantified using FIJI (Schindelin et al., 2012).

443 Statistical analysis

444 All statistical analyses were performed using GraphPad Prism. Values are presented as mean
445 +/- SEM. Statistical significance was assessed using students t-test or a two-way, repeated
446 measures ANOVA with Bonferroni's correction, unless otherwise specified. Significance was

447 indicated by $p < 0.05$. Sample sizes were based on pilot data and are similar to those typically
448 used in the field.

449 For analysis of effects of intracranial microinjections, a paired students t-test was used to
450 compare the effects of intracranial injection of saline versus SP on behavioral measures. Two-
451 way ANOVA determined a lack of significant sex x SP microinjection interaction, so the data
452 from both sexes were pooled. For chemogenetic experiments, a paired t-test was used to
453 compare scratch counts and nociceptive measures following vehicle vs. clozapine or CNO
454 injection, or between vector controls and DREADDs mice following clozapine or CNO. For
455 optogenetic experiments a paired t-test was similarly used to compare behavioral measures
456 during and in the absence of optic stimulation.

457 For experiments with imiquimod, paired students t-tests compared the effects of ip injection of
458 saline versus clozapine on spontaneous scratch bouts and alloknesis scores. A two-way
459 ANOVA revealed no interaction for sex x clozapine administration, so the data were pooled for
460 further analysis.

461 For single-unit recordings, a 2-way repeated measures ANOVA with bonferroni post-hoc test
462 was used to compare the neuronal responses to pinch following intra-RVM injection of saline or
463 SP for 60 minutes post-injection.

464 For immunohistochemical staining for c-fos, students t-test compared the staining intensity of c-
465 fos and the proportion of c-fos positive neurons in Tacr1-expressing neurons following
466 administration of clozapine, in mice receiving DREADDs or control vector injections.

467

468 **References**

- 469 Agostinelli, L. J., & Bassuk, A. G. (2021). Novel inhibitory brainstem neurons with selective
470 projections to spinal lamina I reduce both pain and itch. *Journal of Comparative Neurology*,
471 *529*(8), 2125–2137. <https://doi.org/10.1002/cne.25076>
- 472 Akiyama, T., Carstens, M. I., Ikoma, A., Cevikbas, F., Steinhoff, M., & Carstens, E. (2012).
473 Mouse Model of Touch-Evoked Itch (Alloknesis). *Journal of Investigative Dermatology*,
474 *132*(7), 1886–1891. <https://doi.org/10.1038/jid.2012.52>
- 475 Akiyama, T., Ivanov, M., Nagamine, M., Davoodi, A., Carstens, M. I., Ikoma, A., Cevikbas, F.,
476 Kempkes, C., Buddenkotte, J., Steinhoff, M., & Carstens, E. (2016). Involvement of TRPV4
477 in serotonin-evoked scratching. *Journal of Investigative Dermatology*, *136*(1), 154–160.
478 <https://doi.org/10.1038/JID.2015.388>
- 479 Barbaro, N. M., Heinricher, M. M., & Fields, H. L. (1986). Putative pain modulating neurons in
480 the rostral ventral medulla: Reflex-related activity predicts effects of morphine. *Brain*
481 *Research*, *366*(1–2), 203–210. [https://doi.org/10.1016/0006-8993\(86\)91296-5](https://doi.org/10.1016/0006-8993(86)91296-5)
- 482 Bartels, D. J. P., Van Laarhoven, A. I. M., Van de Kerkhof, P. C. M., & Evers, A. W. M. (2018).
483 Nocebo effects and scratching behaviour on itch. *Acta Dermato-Venereologica*, *98*(10),
484 943–950. <https://doi.org/10.2340/00015555-2979>
- 485 Behbehani, M. M., & Fields, H. L. (1979). Evidence that an excitatory connection between the
486 periaqueductal gray and nucleus raphe magnus mediates stimulation produced analgesia.
487 *Brain Research*, *170*(1), 85–93. [https://doi.org/10.1016/0006-8993\(79\)90942-9](https://doi.org/10.1016/0006-8993(79)90942-9)
- 488 Brink, T. S., Pacharinsak, C., Khasabov, S. G., Beitz, A. J., & Simone, D. A. (2012). Differential
489 modulation of neurons in the rostral ventromedial medulla by neurokinin-1 receptors.
490 *Journal of Neurophysiology*, *107*(4), 1210–1221. <https://doi.org/10.1152/jn.00678.2011>

- 491 Budai, D., Khasabov, S. G., Mantyh, P. W., & Simone, D. A. (2007). NK-1 Receptors Modulate
492 the Excitability of ON Cells in the Rostral Ventromedial Medulla. *J Neurophysiol*, *97*, 1388–
493 1395. <https://doi.org/10.1152/jn.00450.2006>
- 494 Butler, R. K., & Finn, D. P. (2009). Stress-induced analgesia. In *Progress in Neurobiology* (Vol.
495 88, Issue 3, pp. 184–202). Pergamon. <https://doi.org/10.1016/j.pneurobio.2009.04.003>
- 496 Carstens, E., Carstens, M. I., Simons, C. T., & Jinks, S. L. (2010). Dorsal horn neurons
497 expressing NK-1 receptors mediate scratching in rats. *NeuroReport*, *21*(4), 303–308.
498 <https://doi.org/10.1097/WNR.0b013e328337310a>
- 499 Carstens, E., Follansbee, T. L., & Carstens, M. I. (2020). The Challenge of Basic Itch Research.
500 *Acta Dermato Venereologica*, *100*: adc00, 2–9. <https://doi.org/10.2340/00015555-3343>
- 501 Carstens, Earl, Iodi Carstens, M., Akiyama, T., Davoodi, A., & Nagamine, M. (2018). Opposing
502 effects of cervical spinal cold block on spinal itch and pain transmission. *Itch*, *3*(3), 1.
503 <https://doi.org/10.1097/itx.0000000000000016>
- 504 Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., & Yaksh, T. L. (1994). Quantitative
505 assessment of tactile allodynia in the rat paw. *Journal of Neuroscience Methods*, *53*(1),
506 55–63. [https://doi.org/10.1016/0165-0270\(94\)90144-9](https://doi.org/10.1016/0165-0270(94)90144-9)
- 507 Chebbi, R., Boyer, N., Monconduit, L., Artola, A., Luccarini, P., & Dallel, R. (2014). The nucleus
508 raphe magnus OFF-cells are involved in diffuse noxious inhibitory controls. *Experimental*
509 *Neurology*, *256*, 39–45. <https://doi.org/10.1016/j.expneurol.2014.03.006>
- 510 Chen, T., Wang, X. L., Qu, J., Wang, W., Zhang, T., Yanagawa, Y., Wu, S. X., & Li, Y. Q.
511 (2013). Neurokinin-1 receptor-expressing neurons that contain serotonin and gamma-
512 aminobutyric acid in the rat rostroventromedial medulla are involved in pain processing.
513 *Journal of Pain*, *14*(8), 778–792. <https://doi.org/10.1016/j.jpain.2013.02.002>

- 514 Damien, J., Colloca, L., Bellei-Rodriguez, C. É., & Marchand, S. (2018). Pain Modulation: From
515 Conditioned Pain Modulation to Placebo and Nocebo Effects in Experimental and Clinical
516 Pain. In *International Review of Neurobiology* (Vol. 139, pp. 255–296). Academic Press
517 Inc. <https://doi.org/10.1016/bs.irn.2018.07.024>
- 518 Fields, H. L. (2000). Pain modulation: Expectation, opioid analgesia and virtual pain. In *Progress*
519 *in Brain Research* (Vol. 122, pp. 245–253). Elsevier. [https://doi.org/10.1016/s0079-](https://doi.org/10.1016/s0079-6123(08)62143-3)
520 [6123\(08\)62143-3](https://doi.org/10.1016/s0079-6123(08)62143-3)
- 521 Fields, H. L. (2004). State-dependent opioid control of pain. *Nature Reviews Neuroscience*,
522 *5*(7), 565–575. <https://doi.org/10.1038/nrn1431>
- 523 Fields, H. L., & Basbaum, A. I. (1978). Brainstem Control of Spinal Pain-Transmission Neurons.
524 *Annual Review of Physiology*, *40*(1), 217–248.
525 <https://doi.org/10.1146/annurev.ph.40.030178.001245>
- 526 Fields, H. L., & Heinricher, M. M. (1985). Anatomy and physiology of a nociceptive modulatory
527 system. *Philosophical Transactions of the Royal Society of London. Series B, Biological*
528 *Sciences*, *308*(1136), 361–374. <https://doi.org/10.1098/rstb.1985.0037>
- 529 Fields, H. L., & Heinricher, M. M. (1989). Brainstem Modulation of Nociceptor-Driven Withdrawal
530 Reflexes. *Annals of the New York Academy of Sciences*, *563*(1), 34–44.
531 <https://doi.org/10.1111/j.1749-6632.1989.tb42188.x>
- 532 Fields, H. L., Vanegas, H., Hentall, I. D., & Zorman, G. (1983). Evidence that disinhibition of
533 brain stem neurones contributes to morphine analgesia. *Nature*, *306*(5944), 684–686.
534 <https://doi.org/10.1038/306684a0>
- 535 Follansbee, T., Akiyama, T., Fujii, M., Davoodi, A., Nagamine, M., Iodi Carstens, M., &
536 Carstens, E. (2018). Effects of pruritogens and algogens on rostral ventromedial medullary

- 537 ON and OFF cells. *Journal of Neurophysiology*, 120(5), 2156–2163.
- 538 <https://doi.org/10.1152/jn.00208.2018>
- 539 Follansbee, Taylor, Zhou, Y., Wu, X., Delahanty, J., Nguyen, A., Domocos, D., Carstens, M. I.,
540 Hwang, S. T., & Carstens, E. (2019). Signs of chronic itch in the mouse imiquimod model
541 of psoriasiform dermatitis. *Itch*, 4(3), e25. <https://doi.org/10.1097/itx.0000000000000025>
- 542 François, A., Low, S. A., Sypek, E. I., Christensen, A. J., Sotoudeh, C., Beier, K. T.,
543 Ramakrishnan, C., Ritola, K. D., Sharif-Naeini, R., Deisseroth, K., Delp, S. L., Malenka, R.
544 C., Luo, L., Hantman, A. W., & Scherrer, G. (2017). A Brainstem-Spinal Cord Inhibitory
545 Circuit for Mechanical Pain Modulation by GABA and Enkephalins. *Neuron*, 93(4), 822-
546 839.e6. <https://doi.org/10.1016/j.neuron.2017.01.008>
- 547 Gao, T., Dong, L., Qian, J., Ding, X., Zheng, Y., Wu, M., Meng, L., Jiao, Y., Gao, P., Luo, P.,
548 Zhang, G., Wu, C., Shi, X., & Rong, W. (2021). G-Protein-Coupled Estrogen Receptor
549 (GPER) in the Rostral Ventromedial Medulla Is Essential for Mobilizing Descending
550 Inhibition of Itch. *Journal of Neuroscience*, 41(37), 7727–7741.
551 <https://doi.org/10.1523/JNEUROSCI.2592-20.2021>
- 552 Gao, Z. R., Chen, W. Z., Liu, M. Z., Chen, X. J., Wan, L., Zhang, X. Y., Yuan, L., Lin, J. K.,
553 Wang, M., Zhou, L., Xu, X. H., & Sun, Y. G. (2019). Tac1-Expressing Neurons in the
554 Periaqueductal Gray Facilitate the Itch-Scratching Cycle via Descending Regulation.
555 *Neuron*, 101(1), 45-59.e9. <https://doi.org/10.1016/j.neuron.2018.11.010>
- 556 Gomez, J. L., Bonaventura, J., Lesniak, W., Mathews, W. B., Sysa-Shah, P., Rodriguez, L. A.,
557 Ellis, R. J., Richie, C. T., Harvey, B. K., Dannals, R. F., Pomper, M. G., Bonci, A., &
558 Michaelides, M. (2017). Chemogenetics revealed: DREADD occupancy and activation via
559 converted clozapine. *Science*, 357(6350).
560 <http://science.sciencemag.org/content/sci/357/6350/503.full.pdf>

- 561 Hamity, M. V., White, S. R., & Hammond, D. L. (2010). Effects of neurokinin-1 receptor agonism
562 and antagonism in the rostral ventromedial medulla of rats with acute or persistent
563 inflammatory nociception. *Neuroscience*, *165*(3), 902–913.
564 <https://doi.org/10.1016/j.neuroscience.2009.10.064>
- 565 Heinricher, M. M., Tavares, I., Leith, J. L., & Lumb, B. M. (2009). Descending control of
566 nociception: Specificity, recruitment and plasticity. In *Brain Research Reviews* (Vol. 60,
567 Issue 1, pp. 214–225). <https://doi.org/10.1016/j.brainresrev.2008.12.009>
- 568 Herman, A. M., Huang, L., Murphey, D. K., Garcia, I., & Arenkiel, B. R. (2014). Cell type-specific
569 and time-dependent light exposure contribute to silencing in neurons expressing
570 Channelrhodopsin-2. *ELife*, *3*, 1–18. <https://doi.org/10.7554/elife.01481>
- 571 Holden, J. E., & Pizzi, J. A. (2008). Lateral hypothalamic-induced antinociception may be
572 mediated by a substance P connection with the rostral ventromedial medulla. *Brain*
573 *Research*, *1214*, 40–49. <https://doi.org/10.1016/j.brainres.2008.03.051>
- 574 Huang, H., Kuzirian, M. S., Cai, X., Snyder, L. M., Cohen, J., Kaplan, D. H., & Ross, S. E.
575 (2016). Generation of a NK1R-CreER knockin mouse strain to study cells involved in
576 Neurokinin 1 Receptor signaling. *Genesis*, *54*(11), 593–601.
577 <https://doi.org/10.1002/dvg.22985>
- 578 Jennings, E. M., Okine, B. N., Roche, M., & Finn, D. P. (2014). Stress-induced hyperalgesia. In
579 *Progress in Neurobiology* (Vol. 121, pp. 1–18). Elsevier Ltd.
580 <https://doi.org/10.1016/j.pneurobio.2014.06.003>
- 581 Khasabov, S. G., Malecha, P., Noack, J., Tabakov, J., Giesler, G. J., & Simone, D. A. (2017).
582 Hyperalgesia and sensitization of dorsal horn neurons following activation of NK-1
583 receptors in the rostral ventromedial medulla. *Journal of Neurophysiology*, *118*(5), 2727–
584 2744. <https://doi.org/10.1152/jn.00478.2017>

- 585 Khasabov, S. G., Wang, J. C., Simone, D. A., & Strichartz, G. R. (2017). A role for neurokinin-1
586 receptor neurons in the rostral ventromedial medulla in the development of chronic
587 postthoracotomy pain. *Pain*, *158*, 1332–1341.
- 588 Koga, K., Shiraishi, Y., Yamagata, R., Tozaki-Saitoh, H., Shiratori-Hayashi, M., & Tsuda, M.
589 (2020). Intrinsic braking role of descending locus coeruleus noradrenergic neurons in acute
590 and chronic itch in mice. *Molecular Brain*, *13*(1), 1–11.
- 591 Le Bars, D. (2002). The whole body receptive field of dorsal horn multireceptive neurones. In
592 *Brain Research Reviews* (Vol. 40, Issues 1–3, pp. 29–44). [https://doi.org/10.1016/S0165-](https://doi.org/10.1016/S0165-0173(02)00186-8)
593 [0173\(02\)00186-8](https://doi.org/10.1016/S0165-0173(02)00186-8)
- 594 Lin, J. Y., Lin, M. Z., Steinbach, P., & Tsien, R. Y. (2009). Characterization of engineered
595 channelrhodopsin variants with improved properties and kinetics. *Biophysical Journal*,
596 *96*(5), 1803–1814. <https://doi.org/10.1016/j.bpj.2008.11.034>
- 597 Liu, M. Z., Chen, X. J., Liang, T. Y., Li, Q., Wang, M., Zhang, X. Y., Li, Y. Z., Sun, Q., & Sun, Y.
598 G. (2019). Synaptic control of spinal GRPR+ neurons by local and long-range inhibitory
599 inputs. *Proceedings of the National Academy of Sciences of the United States of America*,
600 *116*(52), 27011–27017. <https://doi.org/10.1073/pnas.1905658116>
- 601 Ljungdahl, Å., Hökfelt, T., & Nilsson, G. (1978). Distribution of substance P-like
602 immunoreactivity in the central nervous system of the rat-I. Cell bodies and nerve
603 terminals. *Neuroscience*, *3*(10). [https://doi.org/10.1016/0306-4522\(78\)90116-1](https://doi.org/10.1016/0306-4522(78)90116-1)
- 604 Lockwood, S., & Dickenson, A. H. (2020). What goes up must come down: insights from studies
605 on descending controls acting on spinal pain processing. In *Journal of Neural Transmission*
606 (Vol. 127, Issue 4, pp. 541–549). Springer. <https://doi.org/10.1007/s00702-019-02077-x>
- 607 Mayer, D. J., Wolfle, T. L., Akil, H., Carder, B., & Liebeskind, J. C. (1971). Analgesia from

- 608 electrical stimulation in the brainstem of the rat. *Science*, 174(4016), 1351–1354.
609 <https://doi.org/10.1126/science.174.4016.1351>
- 610 Millan, M. J. (2002). Descending control of pain. In *Progress in Neurobiology* (Vol. 66, Issue 6,
611 pp. 355–474). [https://doi.org/10.1016/S0301-0082\(02\)00009-6](https://doi.org/10.1016/S0301-0082(02)00009-6)
- 612 Ossipov, M. H., Morimura, K., & Porreca, F. (2014). Descending pain modulation and
613 chronification of pain. In *Current Opinion in Supportive and Palliative Care* (Vol. 8, Issue 2,
614 pp. 143–151). Lippincott Williams and Wilkins.
615 <https://doi.org/10.1097/SPC.0000000000000055>
- 616 Pinto, M., Sousa, M., Lima, D., & Tavares, I. (2008). Participation of μ -opioid, GABA B , and
617 NK1 receptors of major pain control medullary areas in pathways targeting the rat spinal
618 cord: Implications for descending modulation of nociceptive transmission. *The Journal of*
619 *Comparative Neurology*, 510(2), 175–187. <https://doi.org/10.1002/cne.21793>
- 620 Reynolds, D. V. (1969). Surgery in the rat during electrical analgesia induced by focal brain
621 stimulation. *Science*, 164(3878), 444–445. <https://doi.org/10.1126/science.164.3878.444>
- 622 Saffroy, M., Torrens, Y., Glowinski, J., & Beaujouan, J. C. (2003). Autoradiographic distribution
623 of tachykinin NK2 binding sites in the rat brain: Comparison with NK1 and NK3 binding
624 sites. *Neuroscience*, 116(3), 761–773. [https://doi.org/10.1016/S0306-4522\(02\)00748-0](https://doi.org/10.1016/S0306-4522(02)00748-0)
- 625 Samineni, V. K., Grajales-Reyes, J. G., Copits, B. A., O'Brien, D. E., Trigg, S. L., Gomez, A. M.,
626 Bruchas, M. R., & Gereau, R. W. (2017). Divergent modulation of nociception by
627 glutamatergic and GABAergic neuronal subpopulations in the periaqueductal gray. *ENeuro*,
628 4(2). <https://doi.org/10.1523/ENEURO.0129-16.2017>
- 629 Samineni, V. K., Grajales-Reyes, J. G., Sundaram, S. S., Yoo, J. J., Gereau, R. W., & Gereau
630 Iv, R. W. (2019). Cell type-specific modulation of sensory and affective components of itch

- 631 in the periaqueductal gray. *Nature Communications*, *10*(1), 1–15.
632 <https://doi.org/10.1038/s41467-019-12316-0>
- 633 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch,
634 S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J. Y., White, D. J., Hartenstein, V.,
635 Eliceiri, K., Tomancak, P., & Cardona, A. (2012). Fiji: An open-source platform for
636 biological-image analysis. In *Nature Methods* (Vol. 9, Issue 7, pp. 676–682).
637 <https://doi.org/10.1038/nmeth.2019>
- 638 Todd, A. J. (2010). Neuronal circuitry for pain processing in the dorsal horn. *Nature Reviews*
639 *Neuroscience*, *11*(12), 823–836. <https://doi.org/10.1038/nrn2947>
- 640 Vanegas, H., Barbaro, N. M., & Fields, H. L. (1984). Tail-flick related activity in medullospinal
641 neurons. *Brain Research*, *321*(1), 135–141. [https://doi.org/10.1016/0006-8993\(84\)90689-9](https://doi.org/10.1016/0006-8993(84)90689-9)
- 642 Wager, T. D., & Atlas, L. Y. (2015). The neuroscience of placebo effects: Connecting context,
643 learning and health. In *Nature Reviews Neuroscience* (Vol. 16, Issue 7, pp. 403–418).
644 Nature Publishing Group. <https://doi.org/10.1038/nrn3976>
- 645 Wu, Z. H., Shao, H. Y., Fu, Y. Y., Wu, X. B., Cao, D. L., Yan, S. X., Sha, W. L., Gao, Y. J., &
646 Zhang, Z. J. (2021). Descending Modulation of Spinal Itch Transmission by Primary
647 Somatosensory Cortex. *Neuroscience Bulletin*, *37*(9), 1345–1350.
648 <https://doi.org/10.1007/S12264-021-00713-9/FIGURES/2>
- 649 Yin, J.-B., Wu, H.-H., Dong, Y.-L., Zhang, T., Wang, J., Zhang, Y., Wei, Y.-Y., Lu, Y.-C., Wu, S.-
650 X., Wang, W., & Li, Y.-Q. (2014). Neurochemical properties of BDNF-containing neurons
651 projecting to rostral ventromedial medulla in the ventrolateral periaqueductal gray. *Frontiers*
652 *in Neural Circuits*, *8*, 137. <https://doi.org/10.3389/fncir.2014.00137>
- 653 Zhang, L., & Hammond, D. L. (2009). Substance P enhances excitatory synaptic transmission

654 on spinally projecting neurons in the rostral ventromedial medulla after inflammatory injury.

655 *Journal of Neurophysiology*, 102(2), 1139–1151. <https://doi.org/10.1152/jn.91337.2008>

656 Zhang, S. J., Ye, J., Miao, C., Tsao, A., Cerniauskas, I., Ledergerber, D., Moser, M. B., &

657 Moser, E. I. (2013). Optogenetic dissection of entorhinal-hippocampal functional

658 connectivity. *Science*, 340(6128), 44. <https://doi.org/10.1126/science.1232627>

659


660

661 **Acknowledgements:** We would like to thank Dr. Dong (Johns Hopkins University) for the
662 generous donation of Tac1r-cre mice.

663 **Author Contributions:** T.F., D.D., E.N., A.B., A.N., L.V., M.I.C., and K.T. performed
664 experiments; T.F., M.I.C, E.N., S.R., and E.C. analyzed data; T.F., E.N., S.R., and E.C. edited
665 and revised manuscript; T.F., S.R., and E.C. approved the final version of the manuscript: T.F.,
666 E.C. conceived and designed research, T.F. and E.C. interpreted results of experiments; T.F.
667 and E.C. prepared figures; T.F. and E.C. drafted manuscript.

668

669 **Supplemental Figures**




Supplemental Figure 1. Chemogenetic activation of RVM *Tacr1* expressing neurons inhibits itch related behavior. *Tacr1*creER mice were injected with AAV2-DIO-hM3Dq-mCherry. (A) CNO administration significantly reduced chloroquine evoked scratch bouts in DREADDs but not control vector mice (n = 5-7 males, 5-7 females). (B) CNO reduced spontaneous scratching in hM3Dq-expressing but not control vector mice (n = 5 males, 5 females). (C) CNO administration significantly reduced mechanical withdrawal thresholds in DREADDs but not control vector mice (n = 5-7 males, 5-7 females). (D) CNO did not affect thermal withdrawal latency in any group (n = 5-7 males, 5-7 females).


670

671


672



Supplemental Figure 2: Clozapine administration does not affect acute itch or pain behavior. Saline, low dose clozapine (0.01 mg/kg) or high dose clozapine (0.1 mg/kg) was administered systemically, followed by tests for acute itch and pain behaviors. (A, B) Clozapine did not significantly affect the number of scratch bouts elicited by intradermal injection of histamine (A) or chloroquine (B). (C, D) Clozapine also did not significantly affect the respective latency or threshold of hindlimb withdrawals elicited by acute thermal (C) or mechanical (D) stimuli. (A,C and D) $n = 6$ males, 6 females; (B) $n = 5$ males, 3 females. $P > 0.05$, 1-way ANOVA followed by Bonferroni post hoc test.




Supplemental Figure 3: Efficiency index of classified RVM neurons. (A-C) Identified ON (A), OFF (B), and NEUTRAL (C) cells were tested for efficiency to respond within 20 msec following the onset of an optic stimulus. Neurons which were excited by optic stimulation had a robust efficiency index (approaching or >1) compared to neurons inhibited or unaffected (none) by optic stimulation. (D) Neutral cell doublet.




Supplemental Figure 4: Firing rates of classified RVM neurons in response to optic stimulation.

675



Supplemental Figure 5: Response latency of ON cells to optic stimulation. RVM neurons (n = 17) which responded to optic stimulation at 2 hz, had averaged response latencies of approximately 7.6 +/- 1.12 msec.



Supplemental Figure 6: Sex differences. Graphs are replotted with data sorted into male (blue) and females (red). (A-C) There were no significant sex differences following intramedullary microinjection of saline or SP for histamine- (A) or chloroquine-evoked scratching (B), or for thermal withdrawal latencies (C). (D) Males exhibited a significantly higher mechanical withdrawal threshold following intramedullary saline (\$; $p < 0.001$), while both sexes showed a significant reduction in withdrawal threshold following intramedullary SP. (E) Suppression of histamine-evoked scratching following clozapine was significantly greater in males (#; $p < 0.01$). (F-H) There were no sex differences for chloroquine-evoked scratching (F), thermal withdrawal latency (K) or mechanical withdrawal threshold (H). (I-L) There were no sex difference for histamine- (I) or chloroquine- evoked scratch bouts (J), thermal withdrawal latency (K), or mechanical withdrawal threshold (L).